Carlsmed price target raised to $24 from $21 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Carlsmed (CARL) to $24 from $21 and keeps a Buy rating on the shares after its Q3 earnings beat. The company’s top-line outperformance came from increased surgeon growth coupled with steady productivity of 1.9 units/surgeon, the analyst tells investors in a research note.